本页面由Tiger Trade Technology Pte. Ltd.提供服务

再鼎医药

26.03
-0.1400-0.53%
盘后25.55-0.4800-1.84%19:30 EDT
成交量:114.10万
成交额:2,963.63万
市值:29.25亿
市盈率:-15.29
高:26.18
开:25.77
低:25.55
收:26.17
52周最高:34.72
52周最低:15.96
股本:1.12亿
流通股本:9,711.04万
量比:0.95
换手率:1.17%
股息:- -
股息率:- -
每股收益(TTM):-1.7030
每股收益(LYR):-1.6026
净资产收益率:-26.91%
总资产收益率:-14.75%
市净率:4.82
市盈率(LYR):-16.24

数据加载中...

2026/08/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/12

关联方拟减持公告

Form 144 | Zai Lab Ltd董事 William Lis 计划减持8506股,总价约$212650
2026/08/11

关联方拟减持公告

Form 144 | Zai Lab Ltd 高管 Chen Yajing 拟减持619股,市值约15475美元
2026/08/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/06

重要事件披露

Form 8-K - Current report
2026/06/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/18

重要事件披露

Form 8-K - Current report
2026/06/11

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/21

重要事件披露

Form 8-K - Current report
2026/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]